Clinical Trials Logo

CMML clinical trials

View clinical trials related to CMML.

Filter by:

NCT ID: NCT02418000 Terminated - AML Clinical Trials

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Start date: April 10, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2a dose-escalation study of E6201, a dual mitogen-activated protein kinase/extracellular-signal regulated kinase 1 (MEK1) and FMS-like tyrosine kinase 3 (FLT3) inhibitor, in subjects with advanced hematologic malignancies with documented FLT3 and/or rat sarcoma (Ras) mutations. The Phase1 portion of the study will be a safety run-in (up to 30 subjects) to establish a recommended Phase 2 dose (RP2D). The Ph. 2a portion of the study will evaluate three specific patients groups: Cohort 1 will enroll patients with relapsed or refractory AML and confirmed FLT3 mutation (with or without a Ras mutation) without prior exposure to a FLT3 inhibitor; Cohort 2 will enroll patients with relapsed or refractory AML and confirmed FLT3 mutation (with or without a Ras mutation) with prior exposure to a FLT3 inhibitor; Cohort 3 will enroll patients with relapsed or refractory AML with a confirmed Ras mutation and no FLT3 mutation.

NCT ID: NCT02323178 Completed - Thrombocytopenia Clinical Trials

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Start date: August 7, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of patients with chronic myelomonocytic leukemia (CMML) and thrombocytopenia.

NCT ID: NCT02193958 Completed - AML Clinical Trials

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2a Dose Escalation Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and tolerability. A total of 6 cohorts will be enrolled in Phase 1 to establish the MTD. A total of 20 subjects with MDS/CMML treated at the RP2D are planned, including MDS/CMML subjects treated at the RP2D in Phase 1.

NCT ID: NCT01261312 Completed - AML Clinical Trials

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1-2 dose escalation randomized study in patients with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML patients while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD)as defined in the Dose Escalation Segment.